Financials • NeOnc Technologies

NTHI

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (“FDA”).

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

12/2022

2 financials

12/2024

Year	Revenue	EBITDA	Net Inc	Net Mrg	Equity	ROE	Net Debt	ND/EBITDA	OCF SBC	Capex	FCF	Free SBC	EPS
12/2022	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2024	0	-9	-12	L	-6	L	-0	-	-4	0	4	-4	L

To see all financials—including updated, you must be Premium.